Unicycive Short Long Term Debt Total from 2010 to 2024

UNCY Stock  USD 0.53  0.02  3.92%   
Unicycive Therapeutics Short and Long Term Debt Total yearly trend continues to be fairly stable with very little volatility. Short and Long Term Debt Total will likely drop to about 679.4 K in 2024. During the period from 2010 to 2024, Unicycive Therapeutics Short and Long Term Debt Total regression line of annual values had r-squared of  0.05 and arithmetic mean of  604,357. View All Fundamentals
 
Short and Long Term Debt Total  
First Reported
2010-12-31
Previous Quarter
811 K
Current Value
679.4 K
Quarterly Volatility
547.4 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Unicycive Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Unicycive Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 77.9 K, Net Interest Income of 429.4 K or Depreciation And Amortization of 386.4 K, as well as many indicators such as Price To Sales Ratio of 16.04, Dividend Yield of 0.0 or Days Sales Outstanding of 0.0. Unicycive financial statements analysis is a perfect complement when working with Unicycive Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Unicycive Therapeutics Correlation against competitors.
For more information on how to buy Unicycive Stock please use our How to Invest in Unicycive Therapeutics guide.

Latest Unicycive Therapeutics' Short Long Term Debt Total Growth Pattern

Below is the plot of the Short Long Term Debt Total of Unicycive Therapeutics over the last few years. It is Unicycive Therapeutics' Short and Long Term Debt Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Unicycive Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Short Long Term Debt Total10 Years Trend
Pretty Stable
   Short Long Term Debt Total   
       Timeline  

Unicycive Short Long Term Debt Total Regression Statistics

Arithmetic Mean604,357
Geometric Mean496,983
Coefficient Of Variation90.57
Mean Deviation292,172
Median460,000
Standard Deviation547,357
Sample Variance299.6B
Range2.4M
R-Value0.22
Mean Square Error306.5B
R-Squared0.05
Significance0.42
Slope27,366
Total Sum of Squares4.2T

Unicycive Short Long Term Debt Total History

2024679.4 K
2023811 K
2022155 K
2021306 K
20202.5 M

About Unicycive Therapeutics Financial Statements

Unicycive Therapeutics investors use historical fundamental indicators, such as Unicycive Therapeutics' Short Long Term Debt Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Unicycive Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Short and Long Term Debt Total811 K679.4 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Unicycive Stock Analysis

When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.